Last reviewed · How we verify
Supergene, LLC — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| non-immunogenic staphylokinase | non-immunogenic staphylokinase | phase 3 | Fibrinolytic agent | Plasminogen | Cardiovascular | |
| Non-immunogenic recombinant staphylokinase | Non-immunogenic recombinant staphylokinase | phase 3 | Fibrinolytic agent / Plasminogen activator | Plasminogen | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Capital Medical University · 1 shared drug class
- Kedrion S.p.A. · 1 shared drug class
- University of North Carolina, Chapel Hill · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Supergene, LLC:
- Supergene, LLC pipeline updates — RSS
- Supergene, LLC pipeline updates — Atom
- Supergene, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Supergene, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/supergene-llc. Accessed 2026-06-10.